MedTrace Logo

Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease

NCT02073526 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1230

Last updated 2016-12-06

No results posted yet for this study

Summary

Drug serum concentrations will be measured at several time-points for inflammatory disease patients treated with anti-TNF agents. The purpose is to determine which patients that will clinically benefit from either discontinue treatment, adjusting the dose, switch to another anti-TNF agent or a different class of medication.

Conditions

Interventions

DRUG

Infliximab, adalimumab, certolizumab pegol

Patients are treated with the above mentioned drugs decided by clinicians

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Knut EA Lundin, Prof. · Oslo University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2016-05-31
Completion
2016-11-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02073526 on ClinicalTrials.gov